HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.

Abstract
The efficacy of triple therapy for Helicobacter pylori infection has dramatically declined over the last decade, largely related to increasing clarithromycin resistance rates. From a microbiological standpoint, bismuth quadruple therapy is the ideal replacement since it combines drugs for which resistance does not impair its efficacy. Nonetheless, several obstacles such as availability, complexity or tolerance prevent a general implementation of bismuth quadruple therapy, so non-bismuth quadruple regimens remain the best first-line treatment in clinical practice in many geographical areas. We review the rationale and efficacy of several optimization tools (increasing the length of duration, high-dose acid suppression, probiotics), which have been largely evaluated over the last 5 years to increase the effectiveness of standard triple therapy. Then, we update available evidence on the effectiveness of several non-bismuth quadruple therapies (sequential, concomitant, hybrid, miscellaneous therapy), which have gained interest lately. We also revise evidence on the efficacy of the aforementioned optimization tools for non-bismuth quadruples schemes and, finally we provide a novel regionalized therapeutic algorithm, based on novel formulas recently developed for predicting the outcome of non-bismuth quadruple regimens, upon local antibiotic resistance rates.
AuthorsJavier Molina-Infante, Javier P Gisbert
JournalWorld journal of gastroenterology (World J Gastroenterol) Vol. 20 Issue 30 Pg. 10338-47 (Aug 14 2014) ISSN: 2219-2840 [Electronic] United States
PMID25132750 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Bacterial Agents
  • Proton Pump Inhibitors
  • Clarithromycin
Topics
  • Algorithms
  • Anti-Bacterial Agents (administration & dosage, adverse effects, therapeutic use)
  • Clarithromycin (administration & dosage, adverse effects, therapeutic use)
  • Critical Pathways
  • Drug Administration Schedule
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Helicobacter Infections (diagnosis, drug therapy, microbiology)
  • Helicobacter pylori (drug effects, pathogenicity)
  • Humans
  • Proton Pump Inhibitors (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: